TNFSF11 and lichen planus: The risk of lichen planus is associated with genetically mediated lower expression of TNFSF11, and intriguingly, several case reports suggest lichenoid reaction may be a rarely observed side effect of denosumab, a RANKL (encoded by TNFSF11) inhibitor that has been widely utilized for more than a decade as a treatment for osteoporosis.68